Bioequivalence Study of Nitrofurantoin 100 mg Capsules Under Fed Conditions

This study has been completed.
Sponsor:
Information provided by:
Ranbaxy Inc.
ClinicalTrials.gov Identifier:
NCT00778583
First received: October 22, 2008
Last updated: NA
Last verified: October 2008
History: No changes posted
  Purpose

An open label, randomised, two-treatment, four-period, two-sequence, single-dose, crossover, fully replicated bioavailability study on Nitrofurantoin formulations comparing Nitrofurantoin 100 mg capsules of Ranbaxy Laboratories with Macrobid 100 mg capsules in healthy, adult, human subjects under fed conditions


Condition Intervention
Healthy
Drug: Nitrofurantoin 100 mg capsules

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Official Title: An Open Label, Randomised, Two-Treatment, Four-Period, Two-Sequence, Single-Dose, Crossover, Fully Replicated Bioavailability Study on Nitrofurantoin Formulations Comparing Nitrofurantoin 100 mg Capsules of Ranbaxy Laboratories With Macrobid 100 mg Capsules in Healthy, Adult, Human Subjects Under Fed Conditions

Resource links provided by NLM:


Further study details as provided by Ranbaxy Inc.:

Primary Outcome Measures:
  • Bioequivalence [ Designated as safety issue: No ]

Enrollment: 40
Study Start Date: September 2003
Study Completion Date: December 2003
Primary Completion Date: October 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Nitrofurantoin 100 mg capsules of Ranbaxy
Drug: Nitrofurantoin 100 mg capsules
Active Comparator: 2
Macrobid 100 mg capsules
Drug: Nitrofurantoin 100 mg capsules

Detailed Description:

This was an open-label, randomized, single-dose, four period fully replicate crossover, relative bioavailability study performed on 40 healthy adult male and. A total of 35 completed the clinical phase of the study.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Be in the age range of 18-45 years.
  • Be neither overweight nor underweight for his/her height as per the Life insurance Corporation of India height/weight chart for non-medical cases.
  • Have voluntarily given written informed consent to participate in this study.
  • Be of normal health as determined by medical history and physical examination of the subjects performed within 14 days prior to the commencement of the study.
  • If female and:
  • Of childbearing potential, is practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence; or
  • Is postmenopausal for at least I year; or
  • Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).

Exclusion Criteria:

  • History of allergy to nitrofurantoin and/or other related drugs.
  • Any evidence of organ dysfunction or any clinically significant deviation from the normal, in physical or clinical determinations.
  • Evidence of haemolysis (for glucose-6-phosphotase) deficiency.
  • Presence of disease markers of HIV 1 and 2, Hepatitis B and C viruses or syphilis infection.
  • Female volunteers demonstrating a positive pregnancy test.
  • Female volunteers who are currently breastfeeding.
  • Presence of values which are significantly different from normal reference ranges (as defined in Appendix 5) and/or judged clinically significant for haemoglobin, total white blood cells count, differential WBC count or platelet count.
  • Positive for urinary screen testing of drugs of abuse (opiates and cannabinoids)
  • Presence of values which are significantly different from normal reference ranges (as defined in Appendix 5) and/or judged clinically significant for serum creatinine, blood urea nitrogen, serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), serum alkaline phosphatase, serum bilirubin, plasma glucose or serum cholesterol.
  • Clinically abnormal chemical and microscopic examination of udne defined as presence of RI3C, WBC (>4/HPF), epithelial cells (>4/HPF), glucose (positive) or protein (positive).
  • Clinically abnormal ECG or Chest X-ray. History of serious gastrointestinal, hepatic, renal, cardiovascular, pulmonary, neurological or haematological disease, diabetes, glaucoma or gout.
  • History of any psychiatric illness which may impair the ability to provide written informed consent.
  • Regular smokers who smoke more than 10 cigarettes daily or have difficulty abstaining from smoking for the duration of each study period.
  • History of drug dependence or excessive alcohol intake on a habitual basis of more than 2 units of alcoholic beverages per day (1 unify.equivalent to half pint of beer or ! glass of wine or 1 measure of spirit)or have difficulty in abstaining for the duration of each study period.
  • Use of any enzyme modi~ing drugs within 30 days prior to Day 1 of this study.
  • Participation in any clinical trial within 12 weeks preceding Day ! of this study.
  • A haemoglobin concentration of less than 7 % of lower limit of reference range e.g. 13 gm % for reference range of 14-18 gm at screening.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00778583

Locations
India
Ranbaxy Research Laboratories
Gurgaon, Haryana, India
Sponsors and Collaborators
Ranbaxy Laboratories Limited
  More Information

Additional Information:
No publications provided

Responsible Party: Dr. Tausif Monif, Ranbaxy Research Laboratories
ClinicalTrials.gov Identifier: NCT00778583     History of Changes
Other Study ID Numbers: 024/NITRO-100/03
Study First Received: October 22, 2008
Last Updated: October 22, 2008
Health Authority: India: Drugs Controller General of India

Keywords provided by Ranbaxy Inc.:
Bioequivalence Nitrofurantoin capsules

Additional relevant MeSH terms:
Nitrofurantoin
Anti-Infective Agents, Urinary
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Renal Agents

ClinicalTrials.gov processed this record on April 23, 2014